These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 18460644

  • 1. N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity.
    Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR, Manda VK, Ayers JT, Zhang Z, Deaciuc AG, McIntosh JM, Crooks PA, Bardo MT.
    J Pharmacol Exp Ther; 2008 Aug; 326(2):563-76. PubMed ID: 18460644
    [Abstract] [Full Text] [Related]

  • 2. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices.
    Smith AM, Dhawan GK, Zhang Z, Siripurapu KB, Crooks PA, Dwoskin LP.
    Biochem Pharmacol; 2009 Oct 01; 78(7):889-97. PubMed ID: 19631612
    [Abstract] [Full Text] [Related]

  • 3. bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
    Wooters TE, Smith AM, Pivavarchyk M, Siripurapu KB, McIntosh JM, Zhang Z, Crooks PA, Bardo MT, Dwoskin LP.
    Br J Pharmacol; 2011 May 01; 163(2):346-57. PubMed ID: 21232049
    [Abstract] [Full Text] [Related]

  • 4. r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.
    Beckmann JS, Meyer AC, Pivavarchyk M, Horton DB, Zheng G, Smith AM, Wooters TE, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP.
    Neurochem Res; 2015 Oct 01; 40(10):2121-30. PubMed ID: 26227997
    [Abstract] [Full Text] [Related]

  • 5. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.
    Smith AM, Pivavarchyk M, Wooters TE, Zhang Z, Zheng G, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP.
    Biochem Pharmacol; 2010 Aug 01; 80(3):402-9. PubMed ID: 20346923
    [Abstract] [Full Text] [Related]

  • 6. N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices.
    Grinevich VP, Crooks PA, Sumithran SP, Haubner AJ, Ayers JT, Dwoskin LP.
    J Pharmacol Exp Ther; 2003 Sep 01; 306(3):1011-20. PubMed ID: 12766255
    [Abstract] [Full Text] [Related]

  • 7. Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity.
    Sumithran SP, Crooks PA, Xu R, Zhu J, Deaciuc AG, Wilkins LH, Dwoskin LP.
    AAPS J; 2005 Aug 29; 7(1):E201-17. PubMed ID: 16146341
    [Abstract] [Full Text] [Related]

  • 8. Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).
    Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman P, Papke RL, Bardo MT, Crooks PA.
    Biochem Pharmacol; 2007 Oct 15; 74(8):1271-82. PubMed ID: 17727820
    [Abstract] [Full Text] [Related]

  • 9. Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo.
    Rahman S, Zhang Z, Papke RL, Crooks PA, Dwoskin LP, Bardo MT.
    Br J Pharmacol; 2008 Feb 15; 153(4):792-804. PubMed ID: 18059317
    [Abstract] [Full Text] [Related]

  • 10. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices.
    Wilkins LH, Haubner A, Ayers JT, Crooks PA, Dwoskin LP.
    J Pharmacol Exp Ther; 2002 Jun 15; 301(3):1088-96. PubMed ID: 12023541
    [Abstract] [Full Text] [Related]

  • 11. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors.
    Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP.
    J Pharmacol Exp Ther; 2003 Jan 15; 304(1):400-10. PubMed ID: 12490617
    [Abstract] [Full Text] [Related]

  • 12. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.
    Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA.
    Bioorg Med Chem Lett; 2004 Apr 19; 14(8):1863-7. PubMed ID: 15050617
    [Abstract] [Full Text] [Related]

  • 13. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier.
    Lockman PR, Manda VK, Geldenhuys WJ, Mittapalli RK, Thomas F, Albayati ZF, Crooks PA, Dwoskin LP, Allen DD.
    J Pharmacol Exp Ther; 2008 Jan 19; 324(1):244-50. PubMed ID: 17921191
    [Abstract] [Full Text] [Related]

  • 14. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens.
    Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT.
    Neuropharmacology; 2007 Mar 19; 52(3):755-63. PubMed ID: 17097117
    [Abstract] [Full Text] [Related]

  • 15. Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats.
    Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT.
    Psychopharmacology (Berl); 2006 Mar 19; 184(3-4):426-34. PubMed ID: 16220336
    [Abstract] [Full Text] [Related]

  • 16. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine.
    Miller DK, Sumithran SP, Dwoskin LP.
    J Pharmacol Exp Ther; 2002 Sep 19; 302(3):1113-22. PubMed ID: 12183670
    [Abstract] [Full Text] [Related]

  • 17. The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.
    Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):103-5. PubMed ID: 19000671
    [Abstract] [Full Text] [Related]

  • 18. Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation.
    Zheng G, Zhang Z, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA.
    Bioorg Med Chem Lett; 2007 Dec 15; 17(24):6734-8. PubMed ID: 18029180
    [Abstract] [Full Text] [Related]

  • 19. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement.
    Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, Zanardi A, Rimondini R, Mugnaini M, Clementi F, Chiamulera C, Zoli M.
    J Neurosci; 2010 Apr 14; 30(15):5311-25. PubMed ID: 20392953
    [Abstract] [Full Text] [Related]

  • 20. Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.
    Pivavarchyk M, Smith AM, Zhang Z, Zhou D, Wang X, Toyooka N, Tsuneki H, Sasaoka T, McIntosh JM, Crooks PA, Dwoskin LP.
    Eur J Pharmacol; 2011 May 11; 658(2-3):132-9. PubMed ID: 21371454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.